Organogenesis - ORGO Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ORGO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORGO, but not buy additional shares or sell existing shares.
View ORGO analyst ratings or view top-rated stocks.

2 brokerages have issued 12 month target prices for Organogenesis' stock. Their ORGO share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 439.2% from the stock's current price.
View analysts price targets for ORGO or view top-rated stocks among Wall Street analysts.

Organogenesis' stock was trading at $2.69 on January 1st, 2023. Since then, ORGO shares have decreased by 24.2% and is now trading at $2.04.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our ORGO earnings forecast.

Organogenesis Holdings Inc. (NASDAQ:ORGO) announced its earnings results on Tuesday, November, 9th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. The company had revenue of $113.75 million for the quarter, compared to analysts' expectations of $112.10 million. Organogenesis had a trailing twelve-month return on equity of 9.83% and a net margin of 3.66%. During the same period in the prior year, the firm earned $0.19 EPS.

ETFs with the largest weight of Organogenesis (NASDAQ:ORGO) stock in their portfolio include Janus Henderson Small Cap Growth Alpha ETF (JSML), Strategas Global Policy Opportunities ETF (SAGP), Syntax Stratified SmallCap ETF (SSLY) and Invesco S&P SmallCap Health Care ETF (PSCH).

Organogenesis updated its FY 2023 earnings guidance on Wednesday, March, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $450.00 million-$462.00 million, compared to the consensus revenue estimate of $501.90 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Strongbridge Biopharma (SBBP), vTv Therapeutics (VTVT), Cerecor (CERC), Marker Therapeutics (MRKR), Matinas BioPharma (MTNB), OPKO Health (OPK), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), DURECT (DRRX) and Evofem Biosciences (EVFM).

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

Organogenesis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Soleus Capital Management L.P. (5.62%), AQR Capital Management LLC (1.67%), Morgan Stanley (1.51%), Millennium Management LLC (1.32%), Geode Capital Management LLC (1.12%) and Assenagon Asset Management S.A. (1.10%). Insiders that own company stock include 2016 Organo 10-Year Grat U/ Gn, Albert Erani, Antonio S Montecalvo, Arthur S Leibowitz, Avista Capital Managing Member, Dennis Erani, Gary S Gillheeney, Gary S Gillheeney, Glenn H Nussdorf, Glenn H Nussdorf, Michael W Katz, Michael W Katz, Starr Wisdom and Wayne D Mackie.
View institutional ownership trends.

Shares of ORGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ORGO stock can currently be purchased for approximately $2.04.

Organogenesis (NASDAQ:ORGO) has a market capitalization of $267.61 million and generates $450.89 million in revenue each year. The company earns $15.53 million in net income (profit) each year or $0.13 on an earnings per share basis.

The company employs 1,030 workers across the globe.

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The official website for the company is organogenesis.com. The company can be reached via phone at (781) 575-0775 or via email at organoir@westwicke.com.